Inclusive of all taxes
Nitroglycerin Controlled Release Tablets 2.6 mg are specifically formulated for the targeted management of cardiac conditions such as angina pectoris and other heart-related ailments. The controlled release formulation ensures a steady and prolonged delivery of nitroglycerin, minimizing peaks and troughs in blood concentration and thereby reducing side effects while maintaining therapeutic efficacy. Manufactured under strict WHO-GMP compliance, these tablets meet international pharmacopoeial standards (IP/USP) and are packaged in export-grade blister or strip packs, ensuring durability and ease of distribution in global markets. The product is designed to provide uniform dosage control, significant patient compliance due to controlled release properties, and reliable clinical outcomes in hospital and retail pharmacy settings worldwide. This tablet is an essential pharmaceutical formulation for clinics, hospitals, and healthcare supply chains focused on cardiovascular disease management.
Key Features
| Features | Description |
|---|---|
| Dosage Strength | 2.6 mg per tablet |
| Formulation Type | Controlled Release Tablet |
| Active Ingredient | Nitroglycerin |
| Therapeutic Use | Management of cardiac conditions, including angina pectoris |
| Manufacturing Standard | WHO-GMP certified facilities |
| Packaging | Export-grade blister or strip packs for optimal protection and shipping |
| Regulatory Compliance | Complies with International Pharmacopoeial standards (IP/USP) |
| Shelf Life | As per international regulatory standards |
| Market Suitability | Optimized for export and international pharmaceutical markets |
| Manufacturer | IndiGlobal Exports |
| Attributes | Description |
|---|---|
| Category | Cardiac Pharmaceutical |
| Formulation | Tablet |
| Active Pharmaceutical Ingredient (API) | Nitroglycerin 2.6 mg |
| Dosage Form | Controlled Release |
| Packaging Type | Blister or strip packs |
| Compliance Standards | WHO-GMP, IP/USP Pharmacopoeia |
| Intended Use | Therapeutic management of cardiac diseases |
| Shelf Life Duration | In accordance with regulatory requirements |
| Manufacturer | IndiGlobal Exports |
| Export Capability | Yes, suitable for regulated and semi-regulated international markets |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
The tablets are produced under WHO-GMP certified facilities, comply with international pharmacopoeial standards (IP/USP), and are packaged in export-grade blister or strip packs, ensuring quality, safety, and stability required for global distribution.
The controlled release mechanism provides a steady delivery of nitroglycerin over time, reducing fluctuations in blood levels, minimizing side effects, and improving therapeutic consistency, which enhances patient compliance and treatment outcomes.
Yes, the Nitroglycerin Controlled Release Tablets 2.6 mg are designed for clinical effectiveness and patient safety, making them suitable for prescription dispensing across hospitals and retail pharmacies.
This product is manufactured in WHO-GMP compliant facilities and adheres to pharmacopoeial standards such as IP (Indian Pharmacopoeia) and USP (United States Pharmacopeia), ensuring high quality and efficacy.
The tablets are packaged in export-grade blister or strip packs that ensure protection from moisture, light, and mechanical damage during storage and transit.
Brand: indiglobal exports
Country Of Origin: India
Nitroglycerin Controlled Release Tablets 2.6 mg is a pharmaceutical product indicated for cardiac treatment. This formulation is manufactured with export-quality standards to ensure therapeutic efficacy, consistent dosage, and compliance with international healthcare regulations.
Features:Nitroglycerin Controlled Release Tablets 2.6 mg is developed for the effective management of cardiac conditions, offering reliable performance backed by stringent pharmaceutical standards. Each batch is carefully produced and tested to ensure consistency, safety, and compliance with global export norms.
This formulation supports the clinical treatment and ongoing care of patients with cardiac indications. Commonly prescribed in hospital and retail pharmacy settings, it ensures measurable therapeutic benefit.
Crafted in state-of-the-art facilities, this tablet formulation ensures accuracy in dosing and ease of administration. It is typically available in secure blister or strip packs suitable for bulk export or institutional supply.
The product is manufactured in facilities adhering to WHO-GMP standards and complies with pharmacopoeial quality benchmarks (IP/USP). Ideal for regulated and semi-regulated markets seeking quality-assured medications.
Inclusive of all taxes
You Save: 0
Panchkula , India
Service Provider , Professional Services, Exporter, Wholesaler
GST- 06eogps3248l1zf
